Neuronal dynamin I plays a critical role in the recycling of synaptic vesicles, and thus in nervous system function. We expressed and purified dynamin I to explore potentially clinically useful endocytosis inhibitors and to examine the mechanism of their action. We estimated the IC 50 of nineteen psychotropic drugs for dynamin I. The IC 50 values of two selective serotonin reuptake inhibitors (sertraline and fluvoxamine) were 7.3؎1.0 and 14.7؎1.6 m mM, respectively. Kinetic analyses revealed that fluvoxamine is a noncompetitive inhibitor of dynamin I guanosine triphosphatase (GTPase) with respect to guanosine 5-triphosphate (GTP) and a competitive inhibitor with respect to L-phosphatidylserine (PS). Fluvoxamine may compete with PS for binding to the pleckstrin homology domain of dynamin I. On the other hand, sertraline was a mixed type inhibitor with respect to both GTP and PS. Our results indicate that sertraline and fluvoxamine may regulate the transportation of neurotransmitters by modulating synaptic vesicle endocytosis via the inhibition of dynamin I GTPase.
Eukaryotic cells take up extracellular materials and recycle their membranes by endocytosis, which involves the formation of numerous types of membrane vesicles at the plasma membrane. [1] [2] [3] Vesicles occur in various sizes, ranging from large phagosomes, to smaller clathrin-coated vesicles, to tiny synaptic vesicles. Endocytic mechanisms have many cellular functions, including the uptake of extracellular nutrients, regulation of cell surface receptor expression and signaling, antigen presentation, and maintenance of synaptic transmission.
Synaptic transmission is dependent on the continuous reformation of synaptic vesicles via local membrane recycling. 4, 5) Although the precise mechanisms of synaptic vesicle reformation remain a matter of debate, [6] [7] [8] [9] [10] there is strong evidence for a key role of the guanosine triphosphatase (GTPase) dynamin in this process, [11] [12] [13] [14] [15] as well as in a variety of endocytic reactions in all cell types. 12, [16] [17] [18] [19] Dynamin (Dyn) is thought to oligomerize at the neck of endocytic pits and to mediate neck constriction and fission. 11, 12, 14) Receptor-mediated endocytosis (RME) and synaptic vesicle endocytosis (SVE) utilize many proteins and lipid cofactors. 3, 20) SVE occurs when nerve terminals retrieve empty synaptic vesicles after stimulated exocytosis to enable refilling of these vesicles with neurotransmitters for a new round of exocytosis. Overexpression of GTPase-defective Dyn mutants inhibits both RME and SVE in a variety of cells. 21) Mammals have three dynamins with different expression patterns. 22, 23) Dyn I, II and III are all found in neurons, but Dyn I is neuron-specific and is expressed much more strongly than either of the others. 23) Several observations 12, [23] [24] [25] strongly suggest that Dyn I plays a dedicated and essential role in the recycling of synaptic vesicles and, thus, has a critical role in nervous system function. All dynamins have four functional domains: an N-terminal GTPase domain, a pleckstrin homology (PH) domain, a proline-rich domain (PRD), and an assembly domain also known as the GTPase effector domain (GED).
3)
L-Phosphatidylserine (PS) or phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) binds the PH domain of Dyn, enhances its GTPase activity, 26, 27) and induces cooperative helix assembly. 28) Myristyl trimethyl ammonium bromide (MiTMAB) is surface-active, and it alters protein-lipid interactions. 29, 30) At high concentrations, MiTMAB is a cationic surfactant, as observed for other pharmacologically active cationic amphiphilic compounds, including chlorpromazine, an antipsychotic, and imipramine, an antidepressant. 31) Further, chlorpromazine is well known as an endocytosis inhibitor. 32) Thus, the inhibition of Dyn I GTPase activity by various psychotropic drugs was investigated to explore potentially clinically useful endocytosis inhibitors and to understand their mechanism of action.
MATERIALS AND METHODS

Materials
PfuUltraTM II Fusion HS DNA Polymerase was purchased from Stratagene. Restriction enzymes and the DNA ligation kit ver.2 was purchased from Takara Bio Co., Ltd. TALON Metal Affinity Resin was purchased from Clontech Co., Ltd. The Mono Q 5/50 GL column was purchased from Amersham Biosciences Co., Ltd. PET21a expression vectors and Escherichia coli Rosetta2 (DE3) were purchased from Merck Co., Ltd. Quant-iT Protein Assay kit and Thermo-X reverse transcriptase were purchased from Invitrogen. Other chemicals in this study were of analytical or higher grade.
Construction of Expression Vector for Mus musculus Dyn I and GTPase Domain of Dyn I Three fragments of the Dyn I gene (gi: 116063569) were obtained by PCR from mouse brain cDNA, which was synthesized by Thermo-X reverse transcriptase. The GTPase domain (amino acid residues (aa). 1-230) of Dyn I was amplified by using primer 1 (5Ј-GGAATTCAGATCTCATATGGGCAACC-Some Selective Serotonin Reuptake Inhibitors Inhibit Dynamin I Guanosine Triphosphatase (GTPase) Masahiro and primer 6 (5Ј-GGAATTCTTAAGCCTCGAGTAAGTC-TAAGAGGGGAGCCT-3Ј). The amplified gene was digested with Bst BI and Xho I. All of the digested products were ligated into Nde I and Xho I sites in pET21a to create an expression vector for polyhistidine segment 6 residues in length (His 6 ) tag fused to the C-terminus of Dyn I (Dyn-His 6 ). Primer 1 and primer 2 were employed for PCR, and the product was digested with Nde I and Xho I, and ligated into the same sites in pET21a to create an expression vector for His 6 tag fused to the C-terminus of the GTPase domain of Dyn I. These expression vectors were named pETDyn1 and pETDynGTP, respectively. Successful construction of all expression vectors was confirmed by DNA sequencing. Expression and Purification of Dyn-His 6 E. coli Rosetta2 (DE3) cells were transformed with each of pETDyn1 and pETDynGTP. Cells were cultured in 6 l of LB medium containing 100 mg ml Ϫ1 ampicillin (and 20 mg ml Ϫ1 chloramphenicol at 37°C. At an A 600 of 0.5, expression was induced for 3 h with 300 mM isopropyl 1-thio-b-D-galactoside, after which cells were harvested by centrifugation. Subsequent steps were performed at 4°C. The cell pellet was resuspended in 60 ml of Buffer A (50 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, 10 mM imidazole), then disrupted by sonication, and the lysate was centrifuged.
The supernatant was applied to a 1 ml TALON Metal Affinity Resin column equilibrated with Buffer A. The column was washed three times with 10 ml of Buffer B (50 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, 20 mM imidazole), and the bound protein was eluted with 7 ml of Buffer C (20 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, 250 mM imidazole). The eluate was further purified to homogeneity on a MonoQ column, and finally dialyzed against Buffer D (10 mM Tris-HCl pH 8.0, 150 mM NaCl). The purified Dyn-His 6 and GTPase domain were characterized by SDS-PAGE. Protein concentration was determined with a Quant-iT Protein Assay kit (Invitrogen). GTPase Assay The Malachite Green GTPase assay was used for the sensitive colorimetric detection of orthophosphate (Pi) according to the method reported by Quan et al. 33, 34) Purified 20 nM Dyn-His 6 (diluted in dynamin diluting buffer: 6 mM Tris-HCl, 20 mM NaCl, 0.02% Tween 80, pH 7.4) was incubated in GTPase buffer (10 mM Tris-HCl, 10 mM NaCl, 2 mM Mg 2ϩ , 0.05% Tween 80, pH 7.4, 1 mg/ml leupeptin and 0.1 mM PMSF) and guanosine 5Ј-triphosphate (GTP) 0.3 mM in the presence of test compound for 30 min at 30°C. The final assay volume was 40 ml. The assay was conducted in round-bottomed 96-well plates. The incubations of the plate were performed in a dry heating block with shaking at 300 rpm (Eppendorf Thermomixer). Dynamin activity was measured as phospholipid release stimulated with addition of different concentrations of PS liposomes. The reaction was terminated with 10 ml of 0.5 M EDTA pH 8.0. To each well was added 150 ml of Malachite Green solution (2% (w/v) ammonium molybdate tetrahydrate, 0.15% (w/v) malachite green and 1 M HCl: the solution was passed through 0.45 mm filters. Color was allowed to develop for 20 min, and the absorbance of samples in each plate was determined on a microplate spectrophotometer (Wallac 1420 ARVOsx from PerkinElmer) at 650 nm. Phosphate release was quantified by comparison with a standard curve of sodium dihydrogen orthophosphate monohydrate which was run in each experiment. KaleidaGraph 4.0 (Synergy Software) was used for plotting data points and analysis of enzyme kinetics using non-linear regression. The curves were generated using the 
MiTMAB and Psychotropic Drugs
Myristyl trimethyl ammonium bromide (MiTMAB), 5H-dibenz[b, f ]azepine- 5-carboxamide (carbamazepine), 10,11-dihydro-5-[3-(meth- ylamino)propyl]-5H-dibenz[b, f ]azepine monohydrochloride (desipramine), 4-[4-(4-chlorophenyl)-4-hydroxy-1- piperidyl]-1-(4-fluorophenyl)butan-1-one (haloperidol) and (1S )-cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-meth- yl-1-naphthalenamine (sertraline) were from Wako Pure Chemical Industries. N-Methyl-3-phenyl-3-[4-(trifluorometh- yl)phenoxy]propan-1-amine (fluoxetine), 3-(9-chloro-5,6- dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpro- pan-1-amine, (clomipramine), N-methyl-9,10-ethanoanthra- cene-9(10H)-propanamine (maprotiline), 3-(2-chloro-10H- phenothiazin-10-yl)-N,N-dimethylpropan-1-amine (chlorpro- mazine) and 1-[3-(dimethylamino)propyl]-1-(4-flu- orophenyl)-1,3-dihydro[2]benzofuran-5-carbonitrile (citalo- pram) were from Sigma-Aldrich. N-[(1-Ethylpyrrolidin-2- yl)methyl]-2-methoxy-5-sulfamoylbenzamide (sulpiride), 2- ((8-chlorodibenzo(b, f )thiepin
RESULTS
Recombinant Dyn I from E. coli Has GTPase Activity
Although native Dyn I and recombinant Dyn I from the baculovirus expression system have been employed to investigate the GTPase activity of Dyn I, 34, 35) it has not previously been confirmed that recombinant Dyn I from E. coli shows GTPase activity. We expressed and purified dynamin I with a His 6 tag fused to the C-terminus (Dyn-His 6 ) and the GTPase domain of Dyn I from E. coli Rosetta2 (DE3) with a His 6 tag fused to the C-terminus by transforming the cells with pETDyn1 and pETDynGTP (Fig. 1A) . Purified Dyn-His 6 hydrolyzed GTP and released orthophosphate Pi time-dependently. In contrast, release of Pi was not observed in the case of the purified GTPase domain of Dyn I (Fig. 1B) . These results clearly show that purified Dyn-His 6 from E. coli has GTPase activity, while the GTPase domain of Dyn I alone does not.
Some Selective Serotonin Reuptake Inhibitors (SSRIs) Inhibit the GTPase Activity of Dyn I The IC 50 values of MiTMAB (used as a standard inhibitor of Dyn I) and nineteen psychotropic drugs were estimated as shown in Table 1 33) which is rather different from that determined here. This discrepancy may be explained by the difference between native Dyn I from sheep brain used in their study, and recombinant Dyn-His 6 from E. coli used in ours. Therefore, we evaluated the Dyn I inhibitory activity of the nineteen psychotropic drugs by comparing their IC 50 values with that of MiTMAB in the same system. Serotonin/noradrenaline reuptake inhibitor (milnacipran), anticonvulsant (carbamazepine) and the antipsychotics (chlorpromazine, haloperidol, sulpiride, zotepine and tiapride) all showed little inhibition of dynamin I GTPase activity compared with MiTMAB (Table 1) . However, the IC 50 values for two antidepressants (clomipramine and maprotiline) and two SSRIs (fluoxetine and paroxetine) were greater than or similar to the IC 50 for MiTMAB (Table 1) . It is noteworthy that the two SSRIs showed lower IC 50 values (7.3Ϯ 1.0 mM for sertraline and 14.7Ϯ1.6 mM for fluvoxamine, Table 1 ) than MiTMAB. The full concentration response curves are shown in Fig. 2 . Other psychotropic drugs did not inhibit dynamin I GTPase activity (Table 1) .
How Do Sertraline and Fluvoxamine Inhibit Dynamin I GTPase? To investigate whether sertraline and fluvoxamine interfere with the activity of dynamin I GTPase, kinetic analysis of dynamin I GTPase activity in the presence of various concentrations of PS liposomes or GTP was conducted (Fig. 3) .
Kinetic analysis with increasing concentrations of GTP revealed that the maximal velocity of dynamin I GTPase activity, V max , was 573 nmol/mg/min and the Michaelis-Menten constant, K m , was 25.3 mM, as calculated from the line for 0 mM fluvoxamine in Fig. 3B . In the presence of sertraline or fluvoxamine, the V max decreased and K m increased with increasing concentrations of SSRI. The Lineweaver-Burke plots show mixed type inhibition (Figs. 3A-D) .
With PS liposomes, the V max was 593 nmol/mg/min, and the K m was 0.445 mM, as calculated from the line for 0 mM fluvoxamine in Fig. 3F . In the presence of fluvoxamine, there was no effect on V max . On the other hand, K m increased with increasing concentrations of fluvoxamine. These data show that fluvoxamine competes with PS for binding to Dyn I.
Lineweaver-Burke double reciprocal plots indicated competitive inhibition with respect to PS (Fig. 3F) . In the presence of sertraline, V max decreased and K m increased with increasing concentrations of sertraline. The Lineweaver-Burke plots show mixed type inhibition (Figs. 3E-H) . is necessary for tetramerization and higher-order self-assembly. 35 ) Dyn exhibits GTPase activity upon self-assembly and undergoes appreciable conformational changes during its GTP hydrolysis cycle. 28, 36) These observations are consistent with our finding that the GTPase domain of Dyn I did not show GTPase activity. On the other hand, purified Dyn-His 6 from E. coli did show GTPase activity.
It is known that Dyn I is dephosphorylated by the calciumdependent phosphatase calcineurin 37) and is subsequently rephosphorylated by cyclin-dependent kinase 5 (cdk5) on Ser774 and Ser778 during SVE. 38, 39) Although Dyn-His 6 from E. coli would not have undergone post-translational modification, such as phosphorylation, it should be suitable for the present purpose, since it retains GTPase activity at least.
The IC 50 values for sertraline and fluvoxamine (7.3Ϯ 1.0 mM and 14.7Ϯ1.6 mM, Table 1 ) were less than the IC 50 of MiTMAB (Table 1) , so these SSRIs are inhibitors of dynamin I GTPase. The IC 50 value of chlorpromazine was 47.2Ϯ23.1 mM (Table 1) in this study. Given that chlorpromazine is a well-known endocytosis inhibitor, 32) it seems likely that sertraline and fluvoxamine inhibit endocytosis by repressing dynamin I GTPase activity.
MiTMAB is a surface-active compound that competes with PS for binding to the dynamin I PH domain, and it is a noncompetitive inhibitor with respect to GTP. 33) Fluvoxamine showed mixed type inhibition with respect to GTP and competitive inhibition with respect to PS in this study (Fig. 3) . Therefore, it seems that fluvoxamine competes with PS for binding to the dynamin I PH domain, like MiTMAB. Fluvoxamine has a methoxypentylidene group, which may behave like the alkyl chain of MiTMAB.
Sertraline showed mixed type inhibition with respect to GTP and PS (Fig. 3) . We cannot explain the inhibition mechanism of sertraline from the results of this study, but it is clearly different from that of fluvoxamine.
Most of the SSRIs (fluoxetine, paroxetine, sertraline and fluvoxamine) inhibited dynamin I GTPase (Table 1) . Dyn I is expressed at much higher levels than Dyn II and III in neurons, and plays a critical role in nervous system function. [23] [24] [25] We speculate that these SSRIs regulate the transportation of neurotransmitters through the modulation of the synaptic vesicle endocytosis via the inhibition of dynamin I GTPase. 
